Page 31 - Lipids News Today

Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair of early studies.

New capacity will be operational from August 2023

Certain polyunsaturated fatty acids (PUFAs) may have a favorable effect on disease progression and survival for patients with amyotrophic lateral sclerosis.

The FDA has given the new low dose of colchicine a broad indication for use in atherosclerotic cardiovascular disease, but how will the drug actually be used in clinical practice?

Both Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin) were approved for children aged 10 years and older.

An detailed analysis on the worldwide lipid nutrition industry has been released by a reputable market research company, demonstrating the markets i

The question of whether a multidisciplinary post-stroke care program should be judged on its ability to prevent major cardiovascular events at 1 year was raised after a trial showed no benefit.

An investigator with the University of Kansas School of Pharmacy has filed an invention disclosure, part of a provisional patent application with the United States Patent and Trademark Office, for a treatment that could apply to heart disease, stroke and a host of other human diseases related to metabolism.

Cellular stress, or oxidative stress, occurs when there is a buildup of reactive oxygen species (ROS), which interferes with cellular mechanisms and can even cause damage to proteins, lipids, and DNA.

Intensive statin therapy immediately after mild ischemic stroke or high-risk TIA reduces the risk for a poor functional outcome vs delaying 72 hours, the INSPIRES trial shows.